ACW unlisted options fully underwritten
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Actinogen Medical Limited has announced that its unlisted options are fully underwritten, providing significant funding for the company. The underwriting agreement, signed with Forrest Capital Pty Ltd, covers two tranches of options set to expire in September. The company is approaching pivotal trial results for its Alzheimer’s treatment, Xanamem, which are expected soon.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW FY2026 results and outlook
- ACW Appendix 4E and 2026 annual report
- June 2026 Quarterly activity report & Appendix 4C
- Xanamem depression trial published in British J Psychiatry
- ACW third positive XanaMIA trial data committee review
Later from Actinogen Medical
- ACW Alzheimers pivotal trial completes last patient visit
- Underwriting of unlisted options completed
- Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
- ACW September 2026 quarterly activity report & Appendix 4C
- ACW pivotal Alzheimers trial database lock - results mid-Nov
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical